| Literature DB >> 29164079 |
Martha Milade Torres Nupan1, Alberto Velez Van Meerbeke1, Claudia Alejandra López Cabra1, Paula Marcela Herrera Gomez1.
Abstract
AIM: The last systematic review of research on the behavior of children with neurofibromatosis type 1 (NF1) was in 2012. Since then, several important findings have been published. Therefore, the study aim was to synthesize recent relevant work related to this issue.Entities:
Keywords: attention-deficit/hyperactivity disorder; autism spectrum disorder; behavior; cognitive functioning; executive functions; neurofibromatosis; neurofibromatosis type 1; visuospatial functioning
Year: 2017 PMID: 29164079 PMCID: PMC5670111 DOI: 10.3389/fped.2017.00227
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Extraction table including study design, level of evidence (Joanna Briggs Institute levels of evidence), sample characteristics, objectives and results of the studies that addressed cognitive and behavior in children with neurofibromatosis type 1 (NF1).
| Reference | Study design | Level of evidence | Sample | Objectives | Results |
|---|---|---|---|---|---|
| Allen et al. ( | Case–control study | 3d | 23 NF1 | Identify possible relations between neurocognitive ability, facial expression recognition, and social functioning in NF1 children compared with typically developing peers | Children with NF1 had significantly lower parent- and child-rated social functioning per the Pediatric Quality of Life Inventory and greater social problems according to the Child Behavior Checklist. Children with NF1 also had significantly weaker recognition of child faces and adult faces on low intensity conditions |
| Aydin et al. ( | Case–control study | 3d | 37 NF1 | Evaluate the association between the microstructural integrity of CC and neurocognitive disabilities, based on apparent diffusion coefficient and fractional anisotropy values in NF1 children compared with healthy controls | Children with NF1 showed a significantly larger total CC area than healthy controls. Apparent diffusion coefficient values obtained from the CC genu were significantly higher in NF1 children than in healthy controls. There was a negative correlation between the apparent diffusion coefficient values of the CC genu and arithmetic and digit span scores (verbal IQ and performance IQ scores), and between the fractional anisotropy values of the genu and coding scores (verbal IQ and performance IQ scores) in children with NF1 |
| Barquero et al. ( | Clinical trial | lc | 49 NF1 + Reading deficits 17 Idiopathic reading deficit | Determine the effect of remedial reading programs in children with NF1 and reading deficits | Children with NF1 and reading deficiencies responded better to the kinesthetic reading program than the one requiring visual-spatial demands. Similar distribution of reading scores in children with NF1 were found regardless of whether the Conners Parent Rating scores indicated low (T score <50), medium (T score = 50–65), or high risk (T score >65) of ADHD |
| Champion et al. ( | Case–control study | 3d | 46 NF1 Age: 7–17 | Determine the relations between motor impairment, gait variables, and cognitive function in children with NF1 | Normalized scores on the Bruininks-Oseretsky Test of Motor Proficiency, for an NF1 cohort were significantly lower than age-matched normative reference values. Compared with normative data, children with NF1 demonstrated significantly decreased performance on gait parameters. Poorer balance skills were significantly associated with reduced perceptual reasoning and working memory |
| Cosyns et al. ( | Descriptive | 3e | 43 NF1: 14 children, age: 7.4–16; 29, adults, age: 17.9–53.5 | Evaluate the articulation skills of NF1 school children and adults | Children’s phonetic inventory was incomplete for their age: realizations of the sibilants/R/and/or/a/were not totally correct. Distortions were the predominant phonetic error type and rhotacismus non vibrans were frequently observed. There were also substitution and syllable structure errors, particularly deletion of the final consonant of words. Girls tended to display more articulation errors than boys |
| Debrabant et al. ( | Case–control study | 3d | 20 NF1 | Evaluate visual-motor reaction time and its association to the impairment of fine visual-motor skills in children with NF1 | Children with NF1 responded more slowly and with fewer anticipatory responses to predictive stimuli, after controlling for IQ and processing speed. Predictive reaction time performance did not differ from reaction time to unpredicted stimuli, indicating an inability to adopt rhythmic stimuli. All children with NF1 scored below the normal range (percentile 16) on the Movement Assessment Battery for Children, Second edition. Finally, the NF1 group demonstrated a significantly poorer performance on the Beery-Buktenica Developmental Test of Visual-Motor Integration copy test, showing reduced visual-motor integration and tracing outcomes (eye–hand coordination) |
| Galasso et al. ( | Case–control study | 3d | 18 NF1 | Evaluate specific planning deficits in children with NF1 in relation to ADHD comorbidity | They found no correlation between Tower of London test scores and Conners ratings scale for parents’ scores in children with NF1. The authors concluded that planning and problem-solving deficits are not directly related to inattention level |
| Gilboa et al. ( | Case–control study | 3d | 30 NF1 | Evaluate NF1 children performance in lower and higher processes required for intact writing; and to identify predictors of the written product’s spatial arrangement and content | Children with NF1 performed significantly poorer on higher-level processes, evaluated using the Rey Complex Figure Test for cognitive planning skills and the Hebrew version of the Wechsler Intelligence Scale for Children for verbal intelligence. Cognitive planning skills predicted the written product’s spatial arrangement and verbal intelligence scores predicted the written content level |
| Gilboa et al. ( | Case–control study | 3d | 29 NF1 | Identify a possible relation between executive function and academic skills in children with NF1 | Children with NF1 performed significantly lower on four of the BRIEF scales (initiate, working memory, plan/organize, and organization of materials) and two subtests of the BADS-C (water and key search). Significant correlations were shown between BADS-C subtest scores and ACES scale scores: children who scored higher (better performance) on the BADS-C received higher scores (better performance) from their teachers on the ACES. In addition, children who received higher scores (performed better) on the ACES received lower scores from their parents (performed better) on the BRIEF |
| Huijbregts et al. ( | Case–control study | 3d | 15 NF1 | Evaluate volumetric measures of cortical and subcortical brain regions in children with NF1 and its possible association with social skills, attention problems and executive dysfunction | Larger left putamen volume, larger total white matter volume, and smaller precentral gyrus gray matter density in children with NF1 were associated with more social problems (evaluated using Child Behavior Checklist parent ratings). Larger right amygdala volume in children with NF1 was associated with autistic mannerisms (evaluated using Social Responsiveness Scale parent ratings) |
| Isenberg et al. ( | Case–control study | 3d | 55 NF1 | Evaluate attention skills in children with NF1 using measures of visual and sustained auditory attention, divided normative attention, selective attention, and response inhibition | Deficits in sustained visual and auditory attention, and deficits in divided attention and response inhibition were identified in Children with NF1 |
| Lehtonen et al. ( | Case–control study | 3d | 49 NF1 | Evaluate cognitive skills in children with NF1 | Children with NF1 had significantly lower Full-scale |
| Lidzba et al. ( | Retrospective case–control study | 3d | 43 NF1: 16 without ADHD, 27 with ADHD (13 medicated) | Evaluate possible benefits of methylphenidate in cognitive functioning in children with NF1 and comorbid ADHD | Medicated children with NF1 improved significantly in full-scale IQ between two periods of time, this effect was not evident for the other groups. With attention measures as covariates, the effect remained marginally significant. |
| Lidzba et al. ( | Retrospective Case–control study | 3d | 111 NF1: 36 without ADHD, 62 ADD, 13 ADHD. Age range: 6–16 | Evaluation of the influence of ADHD symptoms on the intellectual profile of patients with NF1 | Patients with ADHD symptoms performed significantly worse than those without ADHD symptoms on all intelligence measures (main effects for Full-scale, Verbal, and Performance IQ). Subtests typically impaired in patients with NF1 (visuospatial skills and arithmetic) were not specifically influenced by ADHD symptoms. There were no differences between ADHD subtypes |
| Lion-Francois etal ( | Randomized, double blind, placebo controlled, and crossover trial | lc | 39 NF1 (80 < IQ > 120) Age: 7.9–12.9 | Evaluate possible benefits of methylphenidate in cognitive functioning in children with NF1 and comorbid ADHD | The Simplified Conners’ Parent Rating Scale scores decreased by 3.9 points in medicated children |
| Loitfelder et al. ( | Cross-sectional study | 4b | 14 NF1 | Evaluation of functional connectivity in relation to the cognitive profile of children with NF1 | Associations of increased frontofrontal and functional connectivity with cognitive, social, and behavioral deficits were found. Children and adults with NF1 showed deficient activation of the low-level visual cortex and specific impairment of the magnocellular visual pathway |
| Michael et al. ( | Case–control study | 3d | 20 NF1 | Evaluation of reactivity to visual signals in children with NF1 and its alteration as a possible cause of attention instability | The NF1 group exhibited slower global responses on measures of response time and weakened resistance to interference, leading to difficulties in the ability to continuously focus on a primary task |
| Orraca-Castillo et al. ( | Case–control study | 3d | 32 NF1 | Evaluate children with NF1 through neurocognitive tests dedicated to assess basic capacities which are involved in reading and mathematical achievement | Core numeric capacities do not seem to be responsible for calculation dysfluency in NF1 children. Word decoding deficits and poor number facts retrieval seem to be good predictors of dyslexia and dyscalculia, respectively. A high prevalence of developmental dyslexia was identified |
| Payne et al. ( | Case–control study | 3d | 49 NF1 | Evaluate if executive dysfunction is exacerbated by comorbid diagnosis of ADHD in children with NF1 | Compared with typically developing children, children with NF1 with or without comorbid ADHD demonstrated significant impairment of both spatial working memory (SWM) and inhibitory control. There were no differences between the two NF1 groups in SWM or response inhibition |
| Payne et al. ( | Case–control study | 3d | 71 NF1 | Identify interrelationships between visuospatial learning and other cognitive abilities that may influence performance, such as intelligence, attention and visuospatial function in children with NF1 | Children with NF1 displayed significant impairments in visuospatial learning, with reduced initial retention and poorer learning across repeated trials. Visuospatial learning was inferior in NF1 even after accounting for group differences in intelligence, sustained attention and visuospatial abilities |
| Payne et al. ( | Prospective cohort study | 3c | 18 NF1 | Determine the natural history of cognitive function and T2H from childhood to adulthood and to examine if the presence of discrete T2H in childhood can predict cognitive performance in adulthood | Longitudinal analyses revealed a significant increase in general cognitive function in patients with NF1 over the study period. Improvements were limited to individuals with discrete T2H in childhood. Patients without lesions in childhood exhibited a stable profile. The number of T2H decreased over time, particularly discrete lesions. Lesions located within the cerebral hemispheres and deep white matter were primarily stable, whereas those located in the basal ganglia, thalamus and brainstem tended to resolve |
| Piscitelli et al. ( | Case–control study | 3d | 49 NF1: 32 withT2H in cerebellum, 18 without T2H. Age: 6–16.9 | Evaluate the neuropsychological profile in order to establish the clinical meaning of T2H in the cerebellum of children with NF1 | Patients with T2H in the cerebellum showed a lower IQ than those without. T2H-positive patients showed clinical impairment more frequently than T2H-negative patients, although the group differences were not statistically significant |
| Pride et al. ( | Restrospective case–control study | 3d | 132 NF1 | Determine if cognitive and academic functioning are affected by comorbid ADHD in patients with NF1 | Children with NF1 and ADHD performed significantly worse on measures of mathematical reasoning, receptive language, sustained attention, reading, and spelling compared with children with NF1 only. Children with NF1 and ADHD were also rated more severely by parents and teachers on the BRIEF than the NF1 only group |
| Ribeiro et al. ( | Case–control study | 3d | 17 NF1 | Investigate the neural mechanisms underlying the visual deficits of children with NF1 by using visual evoked potentials and brain oscillations during visual stimulation and rest periods | Abnormal long-latency visual evoked potentials may be related to deficits in high-level processing of visual stimuli; a specific enhancement of alpha brain oscillations related to problems in attention allocation |
| Roy et al. ( | Case–control study | 3d | 36 NF1 | Compare executive functioning profile with characteristics of T2H i children with NF1 | Executive dysfunction in children with NF1 was not significantly influenced by T2H presence, number, size, and location (whole brain or specific areas) |
| Roy et al. ( | Case–control study | 3d | 30 NF1 | Investigate spontaneous versus reactive cognitive flexibility in children with NF1 and their comorbidity with ADHD | NF1 children performed worse than healthy children on both spontaneous and reactive cognitive flexibility tasks, even when intelligence and basic skills were partially excluded. However, ADHD symptomatology did not adversely affect performance |
| Van der Vaart et al. ( | Randomized, double-masked, placebo-controlled trial | lc | 84 NF1: 43 simvastatin, 41 placebo | Assess the use of simvastatin for the improvement of cognitive and behavioral deficits in children with NF1 for 12 months | Simvastatin for 12 months had no effect on full-scale intelligence, attention, and internalizing behavioral problems |
| Violante et al. ( | Case–control study | 3d | 15 NF1 | Investigate the activation pattern of high-level visual and non visual regions modulated by the different stimuli to examine possible functional consequences of low-level visual impairments | Children and adults with NF1 showed deficient activation of the low-level visual cortex, indicating that low-level visual processing deficits do not ameliorate with age. There was specific impairment of the magnocellular visual pathway in early visual processing associated with a deficient deactivation of the default mode network |
| Walsh et al. ( | Retrospective, cross-sectional study | 4b | 66 NF1 | Evaluate systematically, symptoms of autism spectrum disorder in children with NF1 | Forty percent of the NF1 sample showed symptom levels that reached clinical significance on the Social Responsiveness Scale, and 14% showed levels consistent with those seen in children with autism spectrum disorder (ASD). These raised symptom levels were not explained by NF1 disease severity or externalizing and internalizing behavioral disorders. There was a statistically significant relationship between symptoms of ADHD and ASD |
| Wessel et al. ( | Longitudinal cohort study | 3c | 124 NF1 | Determine the age of presentation for specific areas of delay in children with NF1 and the time-dependent progression of these deficits | School-age children exhibited significantly more areas of delay than infants or preschool-age children. Delays in math, reading, gross motor, fine motor, and self-help development were observed more frequently in older than younger children. Analysis of 43 subjects for whom longitudinal assessments were available revealed that children often migrated between delayed and nondelayed groups in all areas except gross motor development |
ACES, Academic Competence Evaluation Scales; BADS-C, Behavioral Assessment of the Dysexecutive Syndrome in Children; BRIEF, Behavior Rating Inventory of Executive Function; CC, Corpus Callosum; ADD, Attention-Deficit Disorder; ADHD, attention-deficit/hyperactivity disorder; JLO, Judgment of Line Orientation; NF1, Neurofibromatosis type 1; T2H, T2-hyperintensities.
Quality evaluation for case–control studies using the Scottish Intercollegiate Guidelines Network (SIGN).
| Reference | Sign methodology checklist: case–control studies | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Internal validity | Overall assessment | |||||||||||||
| 1.1 | 1.2 | 1.3 | 1.4 | 1.5 | 1.6 | 1.7 | 1.8 | 1.9 | 1.10 | 1.11 | 2.1 | 2.2 | 2.3 | |
| Allen et al. ( | YES | YES | NO | Cases: 96% | YES | NO | YES | NA | NA | YES | NO | (+) | NO | NO |
| Controls: 100% | ||||||||||||||
| Aydin et al. ( | YES | YES | NO | Cases: 100% | YES | NO | YES | NA | NA | YES | YES | (+) | NO | NO |
| Controls: 100% | ||||||||||||||
| Champion et al. ( | YES | NA | NA | Cases: 100% | NO | YES | YES | NA | NA | YES | NO | (+) | NO | NO |
| Controls: normative data was used | ||||||||||||||
| Debrabant et al. ( | YES | YES | NO | Cases: 100% | YES | NO | YES | NA | NA | YES | YES | (+) | NO | NO |
| Controls: 100% | ||||||||||||||
| Galasso et al. ( | YES | YES | NO | Cases: 100% | YES | NO | YES | NA | NA | YES | NO | (+) | NO | NO |
| Controls: 100% | ||||||||||||||
| Gilboa et al. ( | YES | YES | NO | Cases: 100% | YES | NO | YES | NA | NA | YES | NO | (+) | NO | NO |
| Controls: 100% | ||||||||||||||
| Gilboa et al. ( | YES | YES | NO | Cases: 100% | YES | NO | YES | NA | NA | YES | NO | (+) | NO | NO |
| Controls: 100% | ||||||||||||||
| Huijbregts et al. ( | YES | CS | CS | Cases: 100% | YES | NO | YES | NA | NA | YES | YES | (+) | NO | NO |
| Controls: 100% | ||||||||||||||
| Isenberg et al. ( | YES | NA | NA | Cases: 19% | NO | YES | YES | NA | NA | YES | NO | (+) | NO | NO |
| Controls: normative data was used | ||||||||||||||
| Lehtonen et al. ( | YES | YES | NO | Cases: 49% | YES | YES | YES | NA | NA | YES | YES | (++) | NO | YES |
| Controls: 100% | ||||||||||||||
| Lidzba et al. ( | YES | YES | NO | Cases: 100% | YES | NO | NO | NA | NA | YES | YES | (+) | NO | NO |
| Controls: 100% | ||||||||||||||
| Lidzba et al. ( | YES | YES | YES | Cases: 100% | YES | YES | YES | NA | NA | YES | NO | (+) | NO | NO |
| Controls:100% | ||||||||||||||
| Michael et al. ( | YES | YES | CS | Cases: 100% | NO | NO | YES | NA | NA | YES | NO | (+) | NO | NO |
| Controls: 100% | ||||||||||||||
| Orraca et al. ( | YES | NA | NA | Cases: 100% | NO | YES | YES | NA | NA | YES | NO | (+) | NO | NO |
| Controls: normative data was used | ||||||||||||||
| Payne et al. ( | YES | YES | NO | Cases: 90% | YES | YES | YES | NA | NA | YES | NO | (++) | NO | YES |
| Controls: 100% | ||||||||||||||
| Payne et al. ( | YES | YES | NO | Cases: 95% | YES | YES | YES | NA | NA | YES | YES | (+) | NO | NO |
| Controls: can’t say | ||||||||||||||
| Piscitelli et al. ( | YES | YES | YES | Cases: 100% | YES | YES | YES | NA | NA | YES | NO | (+) | NO | NO |
| Controls: 100% | ||||||||||||||
| Pride et al. ( | YES | YES | NO | Cases: 100% | YES | NO | YES | NA | NA | YES | NO | (+) | NO | NO |
| Controls: 100% | ||||||||||||||
| Ribeiro et al. ( | YES | YES | NO | Cases: 100% | YES | YES | YES | NA | NA | YES | NO | (+) | NO | NO |
| Controls: 100% | ||||||||||||||
| Roy et al. ( | YES | NA | NA | Cases: 97% | NO | YES | YES | NA | NA | YES | NO | (+) | NO | NO |
| Controls: normative data was used | ||||||||||||||
| Roy et al. ( | YES | YES | YES | Cases: 36.67% | YES | YES | YES | NA | NA | YES | NO | (+) | NO | NO |
| Controls: 100% | ||||||||||||||
| Violante et al. ( | YES | YES | YES | Cases: 60% | YES | YES | YES | NA | NA | YES | NO | (+) | NO | NO |
| Controls: 82% | ||||||||||||||
NA, not applicable; CS, can’t say; (+), acceptable; (++), high quality.
1.1 The study addresses an appropriate and clearly focused question. Yes/no/can’t say.
1.2 The cases and controls are taken from comparable populations. Yes/no/can’t say.
1.3 The same exclusion criteria are used for both cases and controls. Yes/no/can’t say.
1.4 What percentage of each group (cases and controls) participated in the study?
1.5 Comparison is made between participants and non-participants to establish their similarities or differences. Yes/no/can’t say.
1.6 Cases are clearly defined and differentiated from controls. Yes/no/can’t say.
1.7 It is clearly established that controls are non-cases. Yes/no/can’t say.
1.8 Measures will have been taken to prevent knowledge of primary exposure influencing case ascertainment. Yes/no/can’t say/not applicable.
1.9 Exposure status is measured in a standard, valid and reliable way. Yes/no/can’t say.
1.10 The main potential confounders are identified and taken into account in the design and analysis. Yes/no/can’t say.
1.11 Confidence intervals are provided. Yes/no.
2.1 How well was the study done to minimize the risk of bias or confounding? High quality (++), acceptable (+), unacceptable (−).
2.2 Taking into account clinical considerations, your evaluation of the methodology used, and the statistical power of the study, do you think there is clear evidence of an association between exposure and outcome? Yes/no/can’t say.
2.3 Are the results of this study directly applicable to the patient group targeted by this guideline? Yes/no.
Quality evaluation for descriptive studies using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist.
| Reference | Critical appraisal checklist for descriptive studies JBI | Overall appraisal (adapted from quality assessment tool for observational cross-sectional studies NIH) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
| Cosyns et al. ( | NA | UC | YES | YES | NA | NA | NA | YES | YES | Fair |
NA, not applicable; UC, unclear.
1. Was study based on a random or pseudorandom sample? Yes/no/unclear/not applicable.
2. Were the criteria for inclusion in the sample clearly defined? Yes/no/unclear/not applicable.
3. Were confounding factors identified and strategies to deal with them stated? Yes/no/unclear/not applicable.
4. Were outcomes assessed using objective criteria? Yes/no/unclear/not applicable.
5. If comparisons are being made, was there sufficient descriptions of the groups? Yes/no/unclear/not applicable.
6. Was follow up carried out over a sufficient time period? Yes/no/unclear/not applicable.
7. Were the outcomes of people who withdrew described and included in the analysis? Yes/no/unclear/not applicable.
8. Were outcomes measured in a reliable way? Yes/no/unclear/not applicable.
9. Was appropriate statistical analysis used? Yes/no/unclear/not applicable.
10. Quality rating (good, fair, or poor).
Figure 1Systematic review flow diagram.
Quality evaluation for randomized controlled trials using the Scottish Intercollegiate Guidelines Network (SIGN).
| Reference | Sign methodology checklist: randomized controlled trial | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Internal validity | Overall assessment | ||||||||||||
| 1.1 | 1.2 | 1.3 | 1.4 | 1.5 | 1.6 | 1.7 | 1.8 | 1.9 | 1.10 | 2.1 | 2.2 | 2.3 | |
| Barquero et al. ( | YES | YES | YES | YES | YES | NO | YES | Patients with NF1 = 43% | NO | YES | (+) | NO | NO |
| Patients without NF1 = 43 | |||||||||||||
| Lion-Francois et al. ( | YES | YES | YES | YES | YES | NO | YES | Placebo: 0% | YES | NA | (+) | NO | NO |
| MPD: 0% | |||||||||||||
| Van der Vaart et al. ( | YES | YES | YES | YES | YES | NO | Placebo: 4.8% | Simvastatin: 0% | YES | YES | (+) | NO | NO |
NA, not applicable; (+), acceptable; MPD, methylphenidate.
1.1 The study addresses an appropriate and clearly focused question. Yes/no/can’t say.
1.2 The assignment of subjects to treatment groups is randomized. Yes/no/can’t say.
1.3 An adequate concealment method is used. Yes/no/can’t say.
1.4 The design keeps subjects and investigators ‘blind’ about treatment allocation. Yes/no/can’t say.
1.5 The treatment and control groups are similar at the start of the trial. Yes/no/can’t say.
1.6 The only difference between groups is the treatment under investigation. Yes/no/can’t say.
1.7 All relevant outcomes are measured in a standard, valid and reliable way. Yes/no/can’t say.
1.8 What percentage of the individuals or clusters recruited into each treatment arm of the study dropped out before the study was completed?
1.9 All the subjects are analyzed in the groups to which they were randomly allocated (often referred to as intention to treat analysis). Yes/no/can’t say/not applicable.
1.10 Where the study is carried out at more than one site, results are comparable for all sites. Yes/no/can’t say/not applicable.
2.1 How well was the study done to minimize bias? Code as follows: High quality (++), acceptable (+), low quality (−), Unacceptable (−).
2.2 Taking into account clinical considerations, your evaluation of the methodology used, and the statistical power of the study, are you certain that the overall effect is due to the study intervention? Yes/no.
2.3 Are the results of this study directly applicable to the patient group targeted by this guideline? Yes/no.
Quality evaluation for cohort studies using the Scottish Intercollegiate Guidelines Network (SIGN).
| Reference | Sign methodology checklist: cohort studies | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Internal validity | Overall assessment | ||||||||||||||||
| 1.1 | 1.2 | 1.3 | 1.4 | 1.5 | 1.6 | 1.7 | 1.8 | 1.9 | 1.10 | 1.11 | 1.12 | 1.13 | 1.14 | 2.1 | 2.2 | 2.3 | |
| Payne et al. ( | YES | CS | YES | NA | Patients: 55% | NA | YES | YES | NO | YES | NO | YES | CS | NO | (+) | NO | NO |
| Controls: 64.2% | |||||||||||||||||
| Wessel et al. ( | YES | NA | YES | NA | CS | NA | YES | NA | NA | NA | NO | NA | YES | YES | (+) | NO | NO |
NA, not applicable; CS, can’t say; (+), acceptable.
1.1 The study addresses an appropriate and clearly focused question. Yes/no/can’t say.
1.2 The two groups being studied are selected from source populations that are comparable in all respects other than the factor under investigation.
1.3 The study indicates how many of the people asked to take part did so, in each of the groups being studied. Yes/no/not applicable.
1.4 The likelihood that some eligible subjects might have the outcome at the time of enrollment is assessed and taken into account in the analysis.
1.5 What percentage of individuals or clusters recruited into each arm of the study dropped out before the study was completed.
1.6 Comparison is made between full participants and those lost to follow up, by exposure status. Yes/no/can’t say/not applicable.
1.7 The outcomes are clearly defined. Yes/no/can’t say.
1.8 The assessment of outcome is made blind to exposure status. If the study is retrospective this may not be applicable. Yes/no/can’t say/not applicable.
1.9 Where blinding was not possible, there is some recognition that knowledge of exposure status could have influenced the assessment of outcome.
1.10 The method of assessment of exposure is reliable. Yes/no/can’t say/not applicable.
1.11 Evidence from other sources is used to demonstrate that the method of outcome assessment is valid and reliable. Yes/no/can’t say/not applicable.
1.12 Exposure level or prognostic factor is assessed more than once. Yes/no/can’t say/not applicable.
1.13 The main potential confounders are identified and taken into account in the design and analysis. Yes/no/can’t say.
1.14 Have confidence intervals been provided? Yes/no.
2.1 How well was the study done to minimize the risk of bias or confounding? High quality (++), acceptable (+), unacceptable (−).
2.2 Taking into account clinical considerations, your evaluation of the methodology used, and the statistical power of the study, do you think there is clear evidence of an association between exposure and outcome? Yes/no/can’t say.
2.3 Are the results of this study directly applicable to the patient group targeted in this guideline? Yes/no.
Quality evaluation for cross sectional studies using the National Institutes of Health checklist (NIH).
| Reference | Quality assessment tool for observational cohort and cross-sectional studies-NIH | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | |
| Loitfelder et al. ( | YES | YES | NR | YES | YES | NA | NA | NA | NA | NA | NO | NA | NA | NO | Fair |
| Walsh et al. ( | YES | YES | NR | YES | YES | NA | NA | NA | NA | NA | YES | NA | NA | YES | Good |
NA, not applicable; NR, not reported.
1. Was the research question or objective in this paper clearly stated? Yes/no/not applicable/not reported.
2. Was the study population clearly specified and defined? Yes/no/not applicable/not reported.
3. Was the participation rate of eligible persons at least 50%? Yes/no/not applicable/not reported.
4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? Yes/no/not applicable/not reported.
5. Was a sample size justification, power description, or variance and effect estimates provided? Yes/no/not applicable/not reported.
6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured? Yes/no/not applicable/not reported.
7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? Yes/no/not applicable/not reported.
8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)? Yes/no/not applicable/not reported.
9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? Yes/no/not applicable/not reported.
10. Was the exposure(s) assessed more than once over time? Yes/no/not applicable/not reported.
11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? Yes/no/not applicable/not reported.
12. Were the outcome assessors blinded to the exposure status of participants? Yes/no/not applicable/not reported.
13. Was loss to follow-up after baseline 20% or less? Yes/no/not applicable/not reported.
14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? Yes/no/not applicable/not reported.
15. Quality rating (good, fair, or poor).